Heparin-induced Thrombocytopenia (HIT) Clinical Trial
Official title:
Performance Evaluation of the Biological Diagnosis of Heparin-induced Thrombocytopenia (HIT)
Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular weight heparin treatments). It is generally secondary to the appearance of IgG antibodies directed against the platelet factor 4 (PF4) - heparin complex. These antibodies, once bound to this complex, are likely to activate platelets: the thrombotic risk generated can be potentially fatal.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02790567 -
Rapid Diagnosis of Heparin-Induced Thrombocytopenia in Surgical Critically Ill Patients
|
N/A | |
| Recruiting |
NCT03148912 -
Optimizing the Diagnosis of Heparin Induced Thrombocytopenia
|
N/A |